Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Heart Failure Reports
Erschienen in: Current Heart Failure Reports 2/2012

01.06.2012 | Management of Heart Failure (T Meyer, Section Editor)

Chemotherapy-Induced Cardiotoxicity

verfasst von: Amir Y. Shaikh, Jeffrey A. Shih

Erschienen in: Current Heart Failure Reports | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Anthracycline-based chemotherapeutics have long been recognized as effective agents for treating a wide range of malignancies. However, their use is not without significant adverse cardiotoxic side effects. Strategies for prevention involve limiting free-radical production and subsequent cardiac myocyte damage. Dexrazoxane remains the most widely studied cardioprotective medication. Alternative agents may reduce cardiotoxicity but may still cause significant cardiovascular problems. The role of β-blockers and angiotensin-converting enzyme inhibitors in the treatment of heart failure is well proven. The role of these medications in the prevention and treatment of chemotherapy-induced cardiotoxicity is not well established.
Literatur
1.
Geiger S, Lange V, Suhl P, et al. Anticancer therapy induced cardiotoxicity: review of the literature. Anti Canc Drug. 2010;21(6):578–90.CrossRef
2.
•• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer. 2010 Jun 29;10:337. This is a thorough review of the literature. Due to the small trials, meta-analyses are essential with regards to this topic. PubMedCrossRef
3.
Zuppinger C, Suter TM. Cancer therapy-associated cardiotoxicity and signaling in the myocardium. J Cardiovasc Pharmacol. 2010;56(2):141–6.PubMedCrossRef
4.
•• van Dalen EC, Michiels EM, Caron HN, et al. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010 Mar 17;(3):CD005006. Review. Update in: Cochrane Database Syst Rev. 2010;(5):CD005006. This is an effective Cochrane review on preventing or reducing cardiotoxicity from anthracyclines.
5.
Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in survivors of childhood cancer. NEJM. 2006;355(15):1572–82.PubMedCrossRef
6.
• Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009 Jun 16;53(24):2231–47. This is an excellent review on the topic. PubMedCrossRef
7.
Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125:47–58.PubMed
8.
Sawyer DB, Peng X, Chen B, et al. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105–13.PubMedCrossRef
9.
Cardinale D, Colombo A, Torrisi R, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910–6.PubMedCrossRef
10.
Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.PubMedCrossRef
11.
Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol. 2005;23(31):7820–6.PubMedCrossRef
12.
Cheng H, Force T. Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis. 2010;53(2):114–20.PubMedCrossRef
13.
Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation. 2004;109(25):3122–31.PubMedCrossRef
14.
Gharib MI, Burnett AK. Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail. 2002;4(3):235–42.PubMedCrossRef
15.
Quezado ZM, Wilson WH, Cunnion RE, et al. High-dose ifosfamide is associated with severe, reversible cardiac dysfunction. Ann Intern Med. 1993;118(1):31–6.PubMed
16.
Martin M, Pienkowski T, Mackey J, Breast Cancer International Research Group 001 Investigators, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302–13.PubMedCrossRef
17.
Jain M, Townsend RR. Chemotherapy agents and hypertension: a focus on angiogenesis blockade. Curr Hypertens Rep. 2007;9(4):320–8.PubMedCrossRef
18.
Pande A, Lombardo J, Spangenthal E, et al. Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007;27(5B):3465–70.PubMed
19.
Wu S, Chen JJ, Kudelka A, et al. Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis. Lancet Oncol. 2008;9(2):117–23.PubMedCrossRef
20.
Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115–24.PubMedCrossRef
21.
Palumbo A, Rajkumar SV, Dimopoulos MA, International Myeloma Working Group, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414–23.PubMedCrossRef
22.
Barbey JT, Pezzullo JC, Soignet SL. Effect of arsenic trioxide on QT interval in patients with advanced malignancies. J Clin Oncol. 2003;21(19):3609–15.PubMedCrossRef
23.
Albini A, Pennesi G, Donatelli F, et al. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Canc Inst. 2010;102(1):14–25.CrossRef
24.
Ganz WI, Sridhar KS, Ganz SS, et al. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology. 1996;53:461–70.PubMedCrossRef
25.
Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J. 1989;118(1):92–8.PubMedCrossRef
26.
Ewer MS, Ali MK, Gibbs HR, et al. Cardiac diastolic function in pediatric patients receiving doxorubicin. Acta Oncol. 1994;33(6):645–9.PubMedCrossRef
27.
Weesner KM, Bledsoe M, Chauvenet A, et al. Exercise echocardiography in the detection of anthracycline cardiotoxicity. Cancer. 1991;68(2):435–8.PubMedCrossRef
28.
Klewer SE, Goldberg SJ, Donnerstein RL, et al. Dobutamine stress echocardiography: a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin-treated long-term survivors of childhood cancer. J Am Coll Cardiol. 1992;19(2):394–401.PubMedCrossRef
29.
• Sawaya H, Sebag IA, Plana JC, et al. Early detection and predictor of cardiotoxicity in chemotherapy- treated patients. Am J Cardiol. 2011;107:1375–80. This is a recent article reviewing the risk factors, surveillance, and means of identifying cardiotoxicity. PubMedCrossRef
30.
Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36(2):517–22.PubMedCrossRef
31.
Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109(22):2749–54.PubMedCrossRef
32.
Cardinale D, Salvatici M, Sandri MT. Review: role of biomarkers in cardioncology. Clin Chem Lab Med. 2011 Sep 6.
33.
Sandri MT, Salvatici M, Cardinale D, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.PubMedCrossRef
34.
Lefrak EA, Pitha J, Rosenheim S, et al. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973;32:302–14.PubMedCrossRef
35.
Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998;339(13):900–5.PubMedCrossRef
36.
Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risk analysis of 1097 breast cancer patients. J Natl Canc Inst. 2008;100:1058.CrossRef
37.
Posner LE, Dukart G, Goldberg J, et al. Mitoxantrone: an overview of safety and toxicity. Investig New Drugs. 1985;3:123.
38.
Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005–24.PubMedCrossRef
39.
Speyer JL, Green MD, Zeleniuch-Jacquotte A, et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. J Clin Oncol. 1992;10:117–27.PubMed
40.
Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997;15:1318–32.PubMed
41.
Venturini M, Michelotti A, Del Mastro L, et al. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol. 1996;14:3112–20.PubMed
42.
Wexler LH, Andrich MP, Venzon D, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362–72.PubMed
43.
Lopez M, Vici P, Di Lauro K, et al. Randomized prospective clinical trial of highdose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas. J Clin Oncol. 1998;16:86–92.PubMed
44.
Marty M, Espie M, Llombart A, Dexrazoxane Study G, et al. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced metastatic breast cancer patients treated with anthracycline-based chemotherapy. Ann Oncol. 2006;17:614–22.PubMedCrossRef
45.
• van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2008:CD003917. This is a typical Cochrane review on cardioprotective strategies with anthracyclines.
46.
Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2006;48:2258–62.PubMedCrossRef
47.
Waldner R, Laschan C, Lohninger A, et al. Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma. J Cancer Res Clin Oncol. 2006;132:121–8.PubMedCrossRef
48.
Myers C, Bonow R, Palmeri S, et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Semin Oncol. 1983;10:53–5.PubMed
49.
Nakamae H, Tsumura K, Terada Y, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492.PubMedCrossRef
50.
al-Shabanah O, Mansour M, el-Kashef H, et al. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin. Biochem Mol Biol Int. 1998;45:419–27.PubMed
51.
Sacco G, Bigioni M, Evangelista S, et al. Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat. Eur J Pharmacol. 2001;414:71–8.PubMedCrossRef
52.
Vaynblat M, Shah HR, Bhaskaran D, et al. Simultaneous angiotensin converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–6.PubMedCrossRef
53.
• Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55(3):213–20. This is a rare prospective study assessing treatment with standard heart failure medications. Unfortunately, there was no comparative placebo arm. PubMedCrossRef
54.
Yoon GJ, Telli ML, Kao DP, et al. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally? J Am Coll Cardiol. 2010;56:1644.PubMedCrossRef
55.
Fazio S, Calmieri EA, Ferravate B, et al. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998;21:777–9.PubMedCrossRef
56.
Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6:115–9.PubMed
57.
Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol. 2002;13:699–709.PubMedCrossRef
58.
Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol. 2002;20:517–22.
59.
Tallaj JA, Franco V, Rayburn BK, et al. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure. J Heart Lung Transplant. 2005;24:201–19.CrossRef
60.
Musci M, Loebe M, Grauhan O, et al. Heart transplantation for doxorubicin-induced congestive heart failure in children and adolescents. Transplant Proc. 1997;29(1–2):578–9.PubMedCrossRef
61.
Dorent R, Pavie A, Nataf P, et al. Heart transplantation is a valid therapeutic option for anthracycline cardiomyopathy. Transplant Proc. 1995;27(2):1683.PubMed
62.
Christiansen S. Clinical management of doxorubicin-induced heart failure. J Cardiovasc Surg. 2011;52:13–7.
63.
Harris L, Batist G, Belt R, TLC D-99 Study Group, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002;94(1):25–36.PubMedCrossRef
64.
Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol. 2001;19(5):1444–54.PubMed
Metadaten
Titel
Chemotherapy-Induced Cardiotoxicity
verfasst von
Amir Y. Shaikh
Jeffrey A. Shih
Publikationsdatum
01.06.2012
Verlag
Current Science Inc.
Erschienen in
Current Heart Failure Reports / Ausgabe 2/2012
Print ISSN: 1546-9530
Elektronische ISSN: 1546-9549
DOI
https://doi.org/10.1007/s11897-012-0083-y

Weitere Artikel der Ausgabe 2/2012

Current Heart Failure Reports 2/2012 Zur Ausgabe

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

The Neurohormonal Network in the RAAS Can Bend Before Breaking

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

Receptor for Advanced Glycation End Products (RAGE) and Implications for the Pathophysiology of Heart Failure

Pathophysiology: Neuroendocrine, Vascular, and Metabolic Factors (SD Katz, Section editor)

TNF Revisited: Osteoprotegerin and TNF-related Molecules in Heart Failure

Management of Heart Failure (T. Meyer, Section Editor)

Prognostic Value of Combining Echocardiography and Natriuretic Peptide Levels in Patients with Heart Failure

Management of Heart Failure (T Meyer, Section Editor)

Skeletal Muscle Abnormalities in Chronic Heart Failure

Management of Heart Failure (T Meyer, Section Editor)

A Rational Approach to Assess Volume Status in Patients with Decompensated Heart Failure

Neu im Fachgebiet Kardiologie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen